Surx Inc.
This article was originally published in Start Up
Executive Summary
Dissatisfied with current invasive and complicated surgical techniques for stress urinary incontinence (SUI), the founders of [Surx Inc.] believe they can offer a better approach with a minimally invasive outpatient procedure that uses low power radio frequency (RF) to shrink collagen on the pelvic floor, and return stretched tissues to their normal anatomical position. SUI affects some 6.5 million women in the US, and more than 18 million worldwide
You may also be interested in...
The Process of Elimination
Incontinence represents a significant unmet medical need for 20 million Americans that suffer from urge incontinence, and 13 million sufferers of stress incontinence. The market is large, growing, and approachable for small device companies--if they can get funding, that is.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.